Multiple Sclerosis Clinical Care & Research Centre, Department of Neuroscience, Reproductive Science & Odontostomatology, Federico II University, Via Sergio Pansini 5, 80131, Naples, Italy.
Department of Public Health, Federico II University, Via Sergio Pansini 5, 80131, Naples, Italy.
Neurodegener Dis Manag. 2022 Jun;12(3):109-116. doi: 10.2217/nmt-2021-0038. Epub 2022 Apr 21.
Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID, but the impact on healthcare resources and costs remains unknown. In this population-based study, we included 208 natalizumab-treated MS patients who were classified into EID (≤15 infusions in the previous 18 months; n = 51; age = 33.7 ± 11.1 years; female = 72.5%) and SID (>15 infusions in the previous 18 months; n = 157; age = 36.5 ± 10.8 years; female = 68.1%) groups. Natalizumab EID had fewer MS outpatient visits (p = 0.01) and related costs (p = 0.03), and lower natalizumab costs (p < 0.01) compared with SID, without changes in other healthcare resources and costs. Natalizumab EID is associated with reduced direct treatment costs, apparently without additional healthcare burden.
那他珠单抗每 4 周静脉输注 1 次（标准间隔剂量[SID]），适用于复发缓解型多发性硬化症（MS）。与 SID 相比，延长间隔剂量（EID）可降低进行性多灶性白质脑病（PML）的风险，但对医疗资源和成本的影响尚不清楚。在这项基于人群的研究中，我们纳入了 208 名接受那他珠单抗治疗的 MS 患者，这些患者被分为 EID（过去 18 个月内接受≤15 次输注；n=51；年龄=33.7±11.1 岁；女性=72.5%）和 SID（过去 18 个月内接受>15 次输注；n=157；年龄=36.5±10.8 岁；女性=68.1%）组。EID 组 MS 门诊就诊次数（p=0.01）和相关费用（p=0.03）均低于 SID 组，且那他珠单抗费用更低（p<0.01），其他医疗资源和费用则无变化。EID 那他珠单抗治疗与直接治疗费用降低有关，显然不会增加额外的医疗负担。
